CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
Curis, Inc.
Curis, Inc.
AVM Biotechnology Inc
Georgetown University
Cellectar Biosciences, Inc.
Center for International Blood and Marrow Transplant Research
Cancer Research UK
M.D. Anderson Cancer Center
Center for International Blood and Marrow Transplant Research
AbbVie
Cancer Research UK
Cancer Research UK
Cancer Research UK
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Baylor College of Medicine
Baylor College of Medicine
Barbara Ann Karmanos Cancer Institute
Zhejiang DTRM Biopharma
Case Comprehensive Cancer Center
Celgene
Amgen
AO GENERIUM
Celgene
Takeda
Hospices Civils de Lyon
Incyte Corporation
Northwestern University
AbbVie
University of Michigan Rogel Cancer Center
M.D. Anderson Cancer Center
Jonsson Comprehensive Cancer Center
Case Comprehensive Cancer Center
Amgen Research (Munich) GmbH
Baylor College of Medicine
Baylor College of Medicine
National Institutes of Health Clinical Center (CC)
Mayo Clinic
Barbara Ann Karmanos Cancer Institute
Nordic Nanovector
University of Texas Southwestern Medical Center
University of North Carolina, Chapel Hill
Alliance for Clinical Trials in Oncology
Amgen Research (Munich) GmbH
Wake Forest University Health Sciences
Alliance for Clinical Trials in Oncology
Amgen Research (Munich) GmbH
Mayo Clinic
Alliance for Clinical Trials in Oncology
Amgen Research (Munich) GmbH
Radiation Therapy Oncology Group
Alliance for Clinical Trials in Oncology